Previous clinical studies also proved that reduced TET2 expression is correlated with advanced Gleason scores, metastatic disease, and poor prognosis and serves as an independent prognostic marker in PCa (35, 36). This evidence concerns the gene TET2 and posterior cortical atrophy.